# EDGAR Filing Document

**Accession Number:** 0001411690
**File Stem:** 0001411690-26-000011
**Filing Date:** 2026-3
**Character Count:** 28009
**Document Hash:** ed49c571d1a5f345b4570d916fd5ff4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001411690-26-000011.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0001411690-26-000011

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260325

**DATE AS OF CHANGE**: 20260325

**EFFECTIVENESS DATE**: 20260325

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bionano Genomics, Inc.
- **CENTRAL INDEX KEY:** 0001411690
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 261756290
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294598
- **FILM NUMBER:** 26792832

**BUSINESS ADDRESS:**
- **STREET 1:** 9540 TOWNE CENTRE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 888-7600

**MAIL ADDRESS:**
- **STREET 1:** 9540 TOWNE CENTRE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bionano Genomics, Inc
- **DATE OF NAME CHANGE:** 20190308

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioNano Genomics, Inc
- **DATE OF NAME CHANGE:** 20120703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioNanomatrix Inc
- **DATE OF NAME CHANGE:** 20070906

**As filed with the Securities and Exchange Commission on March 25, 2026**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**Bionano Genomics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **Delaware** | **26-1756290** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(I.R.S. Employer**<br>**Identification No.)** |
| <br>**9540 Towne Centre Drive, Suite 100**<br>**San Diego, California** | **92121** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Bionano Genomics, Inc. Amended and Restated 2018 Equity Incentive Plan, as amended**

**Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan**

**(Full titles of the plans)**

**R. Erik Holmlin, Ph.D.**

**President and Chief Executive Officer**

**Bionano Genomics, Inc.**

**9540 Towne Centre Drive, Suite 100**

**San Diego, California 92121**

**(858) 888-7600**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

***Copies to:***

---

| | |
|:---|:---|
| **Rakesh Gopalan**<br>**David S. Wolpa**<br>**Troutman Pepper Locke LLP**<br>**301 S. College Street, Suite 3400**<br>**Charlotte, NC 28202**<br>**(704) 998-4050**<br>| **R. Erik Holmlin, Ph.D.**<br>**President and Chief Executive Officer**<br>**Bionano Genomics, Inc.**<br>**9540 Towne Centre Drive, Suite 100**<br>**San Diego, California 92121**<br>**(858) 888-7600**<br>|

---

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by Bionano Genomics, Inc. (the "***Registrant***") with the Securities and Exchange Commission (the "***SEC***") for the purpose of registering (i) an additional 537,009 shares of Registrant's Common Stock, par value $0.0001 per share ("***Common Stock***"), issuable under the Registrant's 2018 Equity Incentive Plan, as amended (the "***2018 Plan***"), pursuant to the provisions of the 2018 Plan providing for an automatic increase on January 1 of each year in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan and (ii) an additional 366 shares of Common Stock issuable under the Registrant's 2018 Employee Stock Purchase Plan (the "***2018 ESPP***") pursuant to the provisions of the 2018 ESPP providing for an automatic increase on January 1 of each year in the number of shares of Common Stock reserved and available for issuance under the 2018 ESPP. In accordance with the instructional note to Part I of Form S-8 as promulgated by the SEC, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

These additional shares of Common Stock are securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the 2018 Plan and the 2018 ESPP is effective. The Registrant previously registered shares of its Common Stock for issuance under the 2018 Plan and the 2018 ESPP under Registration Statements on Form S-8 as noted below.

The following documents filed by the Registrant with the SEC are incorporated by reference into this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)The contents of the earlier registration statements on Form S-8 pertaining to the 2018 Plan and 2018 ESPP filed with the SEC on [<u>August 28, 2018</u>](https://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702ds8.htm) (File No. 333-227073), [<u>March 29, 2019</u>](https://www.sec.gov/Archives/edgar/data/1411690/000119312519091060/d626460ds8.htm) (File No. 333-230589), [<u>March 11, 2020</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036120005371/nt10009730x2_s8.htm) (File No. 333-237069), [<u>August 14, 2020</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036120018366/nt10014149x1_s8.htm) (File No. 333-245764), [<u>March 24, 2021</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036121009780/nt10022040x2_s8.htm) (File No. 333-254654), [<u>March 1, 2022</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036122007373/brhc10034627_s8.htm) (File No. 333-263176), [<u>March 9, 2023</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036123010941/brhc10049419_s8.htm) (File No. 333-270430), [<u>May 8, 2024</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036124024994/ef20023291_s8.htm) (File No. 333-279229), and [<u>April 2, 2025</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036125011708/ef20046763_s8.htm) (File No. 333-286325);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)The Registrant's Annual Report on Form 10-K for the year ended December 31, 2025, which included audited financial statements for the Registrant's latest fiscal year, filed with the SEC on [<u>March 23, 2026</u>](https://www.sec.gov/Archives/edgar/data/1411690/000141169026000007/bngo-20251231.htm); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)The description of the Registrant's Common Stock contained in a registration statement on Form 8-A filed with the SEC on [<u>July 31, 2018</u>](https://www.sec.gov/Archives/edgar/data/1411690/000119312518233217/d571624d8a12b.htm) (File No. 001-38613) under the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), including any amendment or report filed for the purpose of updating such description including [<u>Exhibit 4.5</u>](https://www.sec.gov/Archives/edgar/data/1411690/000141169024000013/bngo-ex45x20231231.htm) of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on [<u>March 5, 2024</u>](https://www.sec.gov/Archives/edgar/data/1411690/000141169024000013/bngo-20231231.htm).

All reports and other documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, other than Current Reports or portions thereof furnished under Item 2.02 or Item 7.01 or any related Item 9.01 of Form 8-K and exhibits furnished on such form that relate to such items and other portions of documents that are furnished but not filed or are otherwise not incorporated into registration statements pursuant to the applicable rules promulgated by the SEC, after the date of this registration statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities offered hereby then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this registration statement from the date of filing such reports and documents.

Any statement contained in a document incorporated or deemed to be incorporated herein by reference shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or

------

supersedes that statement. Any such statement so modified or superseded shall not constitute a part of this registration statement, except as so modified or superseded.

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 4.1(1) | [<u>Amended and Restated Certificate of Incorporation of the Registrant, as amended</u>](https://www.sec.gov/Archives/edgar/data/1411690/000141169023000082/bngo-2023x09x30xexx31.htm). |
| 4.2(2) | [<u>Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended</u>](https://www.sec.gov/Archives/edgar/data/1411690/000141169025000008/bionano-certificateofamend.htm).  |
| 4.3(3) | [<u>Amended and Restated Bylaws of the Registrant</u>](https://www.sec.gov/Archives/edgar/data/1411690/000119312518257763/d607608dex32.htm). |
| 4.4(4) | [<u>Amendment to Amended and Restated Bylaws.</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036123018454/brhc20051350_ex3-2.htm) |
| 4.5(5) | [<u>Form of Common Stock Certificate of the Registrant.</u>](https://www.sec.gov/Archives/edgar/data/1411690/000119312518219135/d782664dex41.htm) |
| 5.1\* | [<u>Opinion of Troutman Pepper Locke LLP</u>](bngo-ex5_1.htm). |
| 23.1\* | [<u>Consent of BDO USA LLP, Independent Registered Public Accounting Firm</u>](bngo-ex23_1.htm). |
| 23.2\* | [<u>Consent of Troutman Pepper Locke LLP (included as part of Exhibit 5.1)</u>](bngo-ex5_1.htm). |
| 24.1 | [<u>Power of Attorney (included in the signature page to this registration statement).</u>](#powerofattorney) |
| 99.1(6) | [<u>Bionano Genomics, Inc. 2018 Equity Incentive Plan, as amended</u>](https://www.sec.gov/Archives/edgar/data/1411690/000114036120018366/nt10014149x1_ex99-1.htm). |
| 99.2(7) | [<u>Bionano Genomics, Inc. 2018 Employee Stock Purchase Plan</u>](https://www.sec.gov/Archives/edgar/data/1411690/000119312518260602/d616702dex995.htm). |
| 107\* | [<u>Filing Fee Table</u>](bngo-exfiling_fees.htm). |

---

(1) Incorporated by reference to Exhibit 3.1 of the Registrant's Quarterly Report on Form 10-Q, filed with the SEC on November 8, 2023.

(2) Incorporated by reference to Exhibit 3.1 to Registrant's Current Report on Form 8-K, filed with the SEC on January 27, 2025.

(3) Incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K, filed with the SEC on August 24, 2018.

(4) Incorporated by reference to Exhibit 3.2 of the Registrant's Current Report on Form 8-K, filed with the SEC on April 14, 2023.

(5) Incorporated by reference to Exhibit 4.1 of the Registrant's Statement on Form S-1 (File No. 333-225970), as amended, originally filed with the SEC on June 28, 2018).

(6) Incorporated by reference to Exhibit 99.1 of the Registrant's Registration Statement on Form S-8 (File No. 333-245764), filed with the SEC on August 13, 2020.

(7) Incorporated by reference to Exhibit 99.5 of the Registrant's Registration Statement on Form S-8 (File No. 333-227073), filed with the SEC on August 28, 2018.

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 25, 2026.

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**BIONANO GENOMICS, INC.** | &nbsp;&nbsp;&nbsp;**BIONANO GENOMICS, INC.** |
| &nbsp;&nbsp;&nbsp;By: | &nbsp;&nbsp;&nbsp;/s/ R. Erik Holmlin, Ph.D. |
|  | &nbsp;&nbsp;&nbsp;R. Erik Holmlin, Ph.D. |
|  | &nbsp;&nbsp;&nbsp;*President and Chief Executive Officer*<br>|

---

**POWER OF ATTORNEY**

KNOW ALL BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of R. Erik Holmlin, Ph.D. and Mark Adamchak as their true and lawful attorney-in-fact and agent, with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ R. Erik Holmlin, Ph.D. | President, Chief Executive Officer and Director <br>*(Principal Executive Officer and Principal Financial Officer)* | March 25, 2026 |
| R. Erik Holmlin, Ph.D. | President, Chief Executive Officer and Director <br>*(Principal Executive Officer and Principal Financial Officer)* |  |
| /s/ Mark Adamchak | VP, Accounting<br>*(Principal Accounting Officer)* | March 25, 2026 |
| Mark Adamchak | VP, Accounting<br>*(Principal Accounting Officer)* |  |
| /s/ David L. Barker, Ph.D. | Director | March 25, 2026 |
| David L. Barker, Ph.D. | Director |  |
| /s/ Yvonne Linney, Ph.D. | Director | March 25, 2026 |
| Yvonne Linney, Ph.D. | Director |  |
| /s/ Albert A. Luderer, Ph.D. | Director | March 25, 2026 |
| Albert A. Luderer, Ph.D. | Director |  |
| /s/ Hannah Mamuszka | Director | March 25, 2026 |

---

------

---

| | | |
|:---|:---|:---|
| Hannah Mamuszka |  |  |
| /s/ Aleksandar Rajkovic, M.D., Ph.D. | Director | March 25, 2026 |
| Aleksandar Rajkovic, M.D., Ph.D. | Director |  |
| /s/ Christopher Twomey | Director | March 25, 2026 |
| Christopher Twomey | Director |  |
| /s/ Kristiina Vuori, M.D., Ph.D. | Director | March 25, 2026 |
| Kristiina Vuori, M.D., Ph.D. | Director |  |

---

------

## Exhibit 5.1

---

| | |
|:---|:---|
| <br>Troutman Pepper Locke LLP<br>301 S. College Street, 34th Floor<br>Charlotte, NC 28202<br>troutman.com | **Exhibit 5.1**<br>![img81551534_0.gif](img81551534_0.gif) |

---

March 25, 2026

Bionano Genomics, Inc.

9540 Towne Centre Drive, Suite 100

San Diego, California

---

| | |
|:---|:---|
| **Re:** | **Registration Statement on Form S-8** |

---

Ladies and Gentlemen:

We have acted as counsel to Bionano Genomics, Inc., a Delaware corporation (the "**Company**"), in connection with the Registration Statement on Form S-8 (the "**Registration Statement**") that is being filed on the date hereof with the Securities and Exchange Commission (the "**SEC**") by the Company pursuant to the Securities Act of 1933, as amended (the "**Securities Act**"), relating to the registration of an additional 537,009 shares (the "**Shares**") of the Company's common stock, par value $0.0001 per share (the "**Common Stock**"), available for future issuance under the Company's 2018 Equity Incentive Plan, as amended (the "**2018 Plan**"), pursuant to the provisions of the 2018 Plan providing for an automatic increase on January 1 of each year in the number of shares of Common Stock reserved and available for issuance under the 2018 Plan and (ii) an additional 366 shares of Common Stock issuable under the Registrant's 2018 Employee Stock Purchase Plan (the "**2018 ESPP**") pursuant to the provisions of the 2018 ESPP providing for an automatic increase on January 1 of each year in the number of shares of Common Stock reserved and available for issuance under the 2018 ESPP.

In connection with this opinion letter, we have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

For all purposes of the opinion expressed herein, we have assumed, without independent investigation, the following: (a) to the extent that we have reviewed and relied upon certificates of the Company or authorized representatives thereof and certificates and assurances from public officials, all of such certificates, representations and assurances are accurate with regard to factual matters; (b) all documents submitted to us as originals are authentic, complete and accurate, and all documents submitted to us as copies conform to authentic original documents; (c) the genuineness of all signatures; and (d) the Registration Statement will be filed by the Company with the SEC under the Securities Act.

Based on and subject to the foregoing and the exclusions, qualifications, limitations and other assumptions set forth in this opinion letter, we are of the opinion that the Shares have been validly authorized and, when issued and paid for in accordance with and upon the terms and conditions of the 2018 Plan or the 2018 ESPP, as applicable, will be validly issued, fully paid and nonassessable.

------

---

| | |
|:---|:---|
| Bionano Genomics, Inc.<br>March 25, 2026<br>Page 2 | ![img81551534_0.gif](img81551534_0.gif) |

---

The foregoing opinion is limited to the General Corporation Law of the State of Delaware (including statutory provisions and reported judicial decisions interpreting the foregoing), as in effect on the date hereof, and we do not express any opinion concerning any other law.

The foregoing opinion is being furnished only for the purpose referred to in the first paragraph of this opinion letter. We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement. In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act or the rules and regulations of the SEC promulgated thereunder.

Very truly yours,

/s/ Troutman Pepper Locke LLP

Troutman Pepper Locke LLP

------

## Exhibit 23.1

**Exhibit 23.1**

**<u>Consent of Independent Registered Public Accounting Firm</u>**

Bionano Genomics, Inc.

San Diego, California

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 23, 2026, relating to the consolidated financial statements of Bionano Genomics, Inc. (the "Company") appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2025. Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

/s/ BDO USA, P.C.

San Diego, California

March 25, 2026

------

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Bionano Genomics, Inc.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Type**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Security Class Title**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Calculation Rule**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount Registered**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Proposed Maximum Offering Price Per Unit**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Maximum Aggregate Offering Price**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Fee Rate**  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Amount of Registration Fee**  |
| 1 | Equity | 2018 Equity Incentive Plan, as amended Common Stock, $0.0001 par value per share | Other | 537009 | $1.11 | $596079.99 | 0.0001381 | $82.32 |
| 2 | Equity | 2018 Employee Stock Purchase Plan Common Stock, $0.0001 par value per share | Other | 366 | $0.94 | $344.04 | 0.0001381 | $0.05 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $596424.03  |  | $82.37  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $82.37  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Offering Note** <br>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1</sup> (1) In addition to the number of shares of the common stock, par value $0.0001 per share ("Common Stock"), of Bionano Genomics, Inc. (the "Registrant") stated above, pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Common Stock, that become issuable under the Registrant's 2018 Equity Incentive Plan, as amended (the "2018 Plan"), and the Registrant's 2018 Employee Stock Purchase Plan (the "2018 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock of the Registrant. (2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and 457(h) of the Securities Act. The "Proposed Maximum Offering Price Per Unit" and "Maximum Aggregate Offering Price" under the 2018 Plan are calculated using the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on March 19, 2026. The "Proposed Maximum Offering Price Per Unit" and "Maximum Aggregate Offering Price" under the 2018 ESPP are calculated using the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on March 19, 2026, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2018 ESPP. (3) Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 Plan on January 1, 2026 pursuant to an "evergreen" provision contained in the 2018 Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2</sup> (1) In addition to the number of shares of the common stock, par value $0.0001 per share ("Common Stock"), of Bionano Genomics, Inc. (the "Registrant") stated above, pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover any additional shares of Common Stock, that become issuable under the Registrant's 2018 Equity Incentive Plan, as amended (the "2018 Plan"), and the Registrant's 2018 Employee Stock Purchase Plan (the "2018 ESPP") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration which results in an increase in the number of outstanding shares of Common Stock of the Registrant. (2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and 457(h) of the Securities Act. The "Proposed Maximum Offering Price Per Unit" and "Maximum Aggregate Offering Price" under the 2018 Plan are calculated using the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on March 19, 2026. The "Proposed Maximum Offering Price Per Unit" and "Maximum Aggregate Offering Price" under the 2018 ESPP are calculated using the average of the high and low prices of the Common Stock as reported on the Nasdaq Capital Market on March 19, 2026, multiplied by 85%, which is the percentage of the trading price per share applicable to purchasers under the 2018 ESPP. (4) Represents shares of Common Stock that were automatically added to the shares authorized for issuance under the 2018 ESPP on January 1, 2026 pursuant to an "evergreen" provision contained in the 2018 ESPP.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---